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RBaroreflex Activation Therapy
and Resistant Hypertension
Randomization Is Not
Enough, You Should Measure
Blood Pressure Appropriately
We read with interest the elegantly written paper by Bisognano et al.
(1) relating to the double-blind, randomized, placebo-controlled
heos Pivotal Trial, which demonstrated that over the long-term,
aroreflex activation therapy (BAT) can safely reduce systolic blood
ressure (SBP) in patients with resistant hypertension.
We congratulate the authors for this hard-to-perform trial and
he promising results in the field of resistant hypertension. How-
ver, we have some major concerns regarding the failure of the
tudy to meet 1 of the 2 pre-specified primary endpoints of efficacy.
n particular:
. The definition of resistant hypertension was based on 1 outpa-
tient, in-office SBP reading 160 mm Hg after 1 month of
maximally tolerated therapy. A minimum duration of such
therapy for at least 3 months and an in-office SBP reading
160 mm Hg on at least 2 consecutive visits would better
identify patients with true resistant hypertension.
. Although ambulatory SBP 135 mmHg constituted an inclu-
sion criterion, reduction of ambulatory SBP was not considered
an endpoint, thus preventing us from analyzing specific unin-
terpretable findings, such as the larger-than-anticipated reduc-
tion in SBP in patients not receiving BAT and the increased
SD of blood pressure (BP) differences during follow-up. As the
authors noted, the significant reduction of clinical SBP in the
control group during the initial 6 months could not be satis-
factorily justified by possible changes of antihypertensive treat-
ment, Hawthorne effect, or placebo effect. This phenomenon
probably implies either an inappropriate study design (e.g.,
inadequate number of BP measurements) or unsuitable patient
selection. Conversely, such an unusually large and puzzling
“placebo” effect was also present in the referred Darusentan-
Resistant Hypertension Trial (2) and in the African American
Study of Kidney Disease and Hypertension (3). Based on the
above study results, along with the pitfall of arbitrarily selecting
a specific endpoint in time for BP outcome, Bakris et al. (2)
highlighted the importance of ambulatory BP endpoints in the
design of hypertension studies. Similarly, the increased SD of
BP differences during follow-up illustrates the great variability
of BAT on BP reduction and the occurrence of diverse levels of
response to this therapy. Data derived from ambulatory BP
monitoring that demonstrate a sympathetic overactivity, such as
early morning surge, could be identified as predictors of
response to BAT and used in the selection of patients with
resistant hypertension (4).
An additional point closely associated with questioning the
fficacy of BAT is related to the possible changes in antihyperten-
ive treatment during the course of the trial. Did the BATesponders in these 12 months receive a higher dosage or addi-
ional drug classes, such as aldosterone antagonists (which were
sed only by 18% of study participants at baseline)?
Moreover, data on parallel decreases in heart rate (and even at
hat level) and on the presence of comorbidities frequently
ssociated with resistant hypertension (e.g., sleep apnea syndrome,
hronic kidney disease) (5) have not been provided.
Furthermore, the relatively high incidence (25.5%) of
rocedure-related adverse events may suggest that a greater num-
er (2, as required in the present study) of open label implanta-
ions is needed for optimal learning curve, especially in the era of
ercutaneous renal sympathetic denervation (6). In addition, based
n experience with other device implantations (i.e., pacemakers),
tudies of quality of life are needed in the setting of resistant-to-
reatment but still asymptomatic hypertensive patients.
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Reply
We thank Dr. Tsioufis and colleagues for their recent letter
regarding the Rheos Pivotal Trial (1). We provide the following
clarifications based on their original comments.
1. Was blood pressure (BP) adequately characterized in the Rheos
Pivotal Trial? The BpTRU (BpTRU Medical Devices, Coquit-
lam, British Columbia, Canada) repeated-measures protocol (1)
was used throughout the trial to measure BP. BpTRU was selected
